~~<i id='2784E53708'><strike id='2784E53708'><tt id='2784E53708'><pre id='2784E53708'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：leisure time 2025-10-02 19:06:55 Page View：799

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Emergency medicine has repudiated 'excited delirium.' Now what?
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Meta's Zuckerberg and Chan on track to put $50 billion into science

PriscillaChanandMarkZuckerbergonstage,virtually,atthe2023STATSummit.STATMarkZuckerbergandPriscillaCh

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Readout Newsletter: What happened with Sarepta's Duchenne data

AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews